| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.1129200 |
| P698 | PubMed publication ID | 17038624 |
| P2093 | author name string | Hans Schreiber | |
| Hui Liu | |||
| Parastoo Azadi | |||
| Stephen C Meredith | |||
| Andrea Schietinger | |||
| Mary Philip | |||
| Barbara A Yoshida | |||
| P433 | issue | 5797 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molecular chaperones | Q422496 |
| P304 | page(s) | 304-308 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | A mutant chaperone converts a wild-type protein into a tumor-specific antigen | |
| P478 | volume | 314 |
| Q33667213 | A high-throughput O-glycopeptide discovery platform for seromic profiling. |
| Q34552242 | A novel fluorescent assay for T-synthase activity |
| Q41475288 | A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). |
| Q89589976 | Aberrant O-glycosylation contributes to tumorigenesis in human colorectal cancer |
| Q54543468 | Absence of COSMC gene mutations in breast and colorectal carcinomas. |
| Q37581540 | Altered tumor-cell glycosylation promotes metastasis |
| Q41568866 | Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells. |
| Q27661722 | Antibody recognition of a unique tumor-specific glycopeptide antigen |
| Q33860182 | Biochemical characterization of functional domains of the chaperone Cosmc |
| Q38544783 | Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer |
| Q34243372 | Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase |
| Q38869978 | COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. |
| Q41201112 | Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes |
| Q35033249 | Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. |
| Q37994133 | Cancer proteomics |
| Q35525289 | Cancer vaccines and carbohydrate epitopes |
| Q33664810 | Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8). |
| Q37171039 | Comparative glycoproteomics: approaches and applications |
| Q46157360 | Cosmc converter. |
| Q28506209 | Cosmc is an essential chaperone for correct protein O-glycosylation |
| Q58774191 | Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers |
| Q38615601 | Emerging roles of podoplanin in vascular development and homeostasis |
| Q37711887 | Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma |
| Q36491059 | Engineering of mucin-type human glycoproteins in yeast cells. |
| Q36436153 | Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing tn antigen |
| Q88952401 | Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy |
| Q35785378 | Expression of tumour-specific antigens underlies cancer immunoediting |
| Q52709010 | Functional Assays for the Molecular Chaperone Cosmc |
| Q38569702 | Glycosylation in cancer: mechanisms and clinical implications |
| Q37876406 | Golgi pH, its regulation and roles in human disease |
| Q41840726 | Human T cell activation results in extracellular signal-regulated kinase (ERK)-calcineurin-dependent exposure of Tn antigen on the cell surface and binding of the macrophage galactose-type lectin (MGL). |
| Q37727574 | Identification of a novel protein binding motif within the T-synthase for the molecular chaperone Cosmc |
| Q34314283 | Immature truncated O-glycophenotype of cancer directly induces oncogenic features |
| Q36543504 | Immunologic mapping of glycomes: implications for cancer diagnosis and therapy |
| Q36939286 | Immunopathogenesis of IgAN. |
| Q41876001 | Investigation of a new tumor-associated glycosylated antigen as target for dendritic cell vaccination in pancreatic cancer |
| Q35705462 | Lipopeptide-Coated Iron Oxide Nanoparticles as Potential Glycoconjugate-Based Synthetic Anticancer Vaccines |
| Q34424743 | MUC1 glycopeptide epitopes predicted by computational glycomics |
| Q36498123 | Molecular basis of antibody binding to mucin glycopeptides in lung cancer |
| Q39162905 | Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer. |
| Q39974401 | New mutations in C1GALT1C1 in individuals with Tn positive phenotype |
| Q34636909 | Podoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets |
| Q35905327 | Promoters of Human Cosmc and T-synthase Genes Are Similar in Structure, Yet Different in Epigenetic Regulation |
| Q33708026 | Random Glycopeptide Bead Libraries for Seromic Biomarker Discovery |
| Q28080312 | Recent advances in T-cell engineering for use in immunotherapy |
| Q36817899 | Regulation of protein O-glycosylation by the endoplasmic reticulum-localized molecular chaperone Cosmc |
| Q57195324 | Seromic profiling of colorectal cancer patients with novel glycopeptide microarray |
| Q42426240 | Solid-phase synthesis of a pentavalent GalNAc-containing glycopeptide (Tn antigen) representing the nephropathy-associated IgA hinge region |
| Q37236636 | Specificity in cancer immunotherapy |
| Q37706396 | Spleen cells from young but not old immunized mice eradicate large established cancers |
| Q36133931 | Structural Characterization of Mucin O-Glycosylation May Provide Important Information to Help Prevent Colorectal Tumor Recurrence |
| Q38197051 | The Cosmc connection to the Tn antigen in cancer |
| Q37831859 | The Tn antigen-structural simplicity and biological complexity |
| Q36990593 | The adaptive immune response to sporadic cancer |
| Q33593911 | The endoplasmic reticulum chaperone Cosmc directly promotes in vitro folding of T-synthase |
| Q44392892 | The molecular chaperone Cosmc enhances malignant behaviors of colon cancer cells via activation of Akt and ERK. |
| Q34622638 | The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression |
| Q36820030 | The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy |
| Q38031282 | The sweet side of tumor immunotherapy |
| Q35939823 | Tight complex formation between Cosmc chaperone and its specific client non-native T-synthase leads to enzyme activity and client-driven dissociation |
| Q38121846 | Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers |
| Q58708239 | Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes |
| Q34001211 | Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses |
| Q37186248 | Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma |
| Q94093743 | UEG Week 2018 Oral Presentations |
Search more.